Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.

Rezvany, Mohammad Reza

Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. [electronic resource] - British journal of haematology Nov 2006 - 475-85 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

0007-1048

10.1111/j.1365-2141.2006.06324.x doi


Aged
Alemtuzumab
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm--therapeutic use
Antigens, CD--immunology
Antigens, Neoplasm--immunology
Antineoplastic Agents--therapeutic use
CD4-Positive T-Lymphocytes--drug effects
CD52 Antigen
CD8-Positive T-Lymphocytes--drug effects
Complementarity Determining Regions--genetics
DNA, Neoplasm--genetics
Female
Follow-Up Studies
Genes, T-Cell Receptor beta
Glycoproteins--immunology
Humans
Immunoglobulin Variable Region--genetics
Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy
Male
Middle Aged
Pilot Projects
Receptors, Antigen, T-Cell, alpha-beta--genetics
T-Lymphocyte Subsets--drug effects